Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HQ SPCLT PHARMA
HQ SPCLT PHARMA has fifteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and one hundred and four supplementary protection certificates in sixteen countries.
Summary for Hq Spclt Pharma
| International Patents: | 12 |
| US Patents: | 6 |
| Tradenames: | 18 |
| Ingredients: | 12 |
| NDAs: | 15 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-002 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-001 | Apr 7, 2016 | RX | Yes | Yes | 8,835,505 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | SOLUTION;INTRAVENOUS | 205703-002 | Apr 7, 2016 | RX | Yes | Yes | 8,829,054 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | PLATINOL | cisplatin | INJECTABLE;INJECTION | 018057-001 | Approved Prior to Jan 1, 1982 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,177,263 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2906031 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2014143845 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017184188 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | LUC00094 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 0961612 | CA 2009 00036 | Denmark | ⤷ Start Trial | PRODUCT NAME: PACLITAXELALBUMIN |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
